Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression.

Gardenier D, Wisnivesky J, McGinn LK, Kronish IM, McGinn TG.

Gastroenterol Nurs. 2011 Mar-Apr;34(2):102-6. doi: 10.1097/SGA.0b013e31820f9b8f.

PMID:
21455042
2.

Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.

Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM.

J Clin Gastroenterol. 2007 Mar;41(3):322-8.

PMID:
17426475
3.

Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.

Lang JP, Melin P, Ouzan D, Rotily M, Fontanges T, Marcellin P, Chousterman M, Cacoub P; CheObs Study Group.

Antivir Ther. 2010;15(4):599-606. doi: 10.3851/IMP1566.

PMID:
20587853
4.
5.

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy.

Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M.

J Clin Psychiatry. 2003 Jun;64(6):708-14.

PMID:
12823087
6.

Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.

Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB.

Am J Gastroenterol. 2006 Oct;101(10):2254-62.

PMID:
17032190
7.

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.

Mukherjee S, Lyden E, McCashland TM, Schafer DF.

J Gastroenterol Hepatol. 2005 Feb;20(2):198-203.

PMID:
15683421
8.

[Quality assurance in patient addiction treated with drug substitution].

[No authors listed]

Krankenpfl J. 2005;43(7-10):248. German. No abstract available.

PMID:
16515317
9.

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.

Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K.

Hepatology. 2003 Feb;37(2):443-51.

PMID:
12540795
10.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group.

J Hepatol. 2002 May;36(5):672-80.

PMID:
11983451
11.

Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Loftis JM, Matthews AM, Hauser P.

Drugs. 2006;66(2):155-74. Review.

PMID:
16451091
12.

Persistence with hepatitis C therapy in the Department of Veterans Affairs.

Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L.

J Clin Pharm Ther. 2008 Jun;33(3):251-61. doi: 10.1111/j.1365-2710.2008.00912.x.

PMID:
18452412
13.

Treatment of hepatitis C infection for current or former substance abusers in a community setting.

John-Baptiste A, Varenbut M, Lingley M, Nedd-Roderique T, Teplin D, Tomlinson G, Daiter J, Krahn M.

J Viral Hepat. 2009 Aug;16(8):557-67. doi: 10.1111/j.1365-2893.2009.01097.x. Epub 2009 Feb 23.

PMID:
19243498
14.

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group.

Hepatology. 2005 Nov;42(5):1010-8.

PMID:
16250032
15.

Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C.

Castera L, Constant A, Henry C, Champbenoit P, Bernard PH, De Ledinghen V, Demotes-Mainard J, Couzigou P.

Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30.

16.

Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.

Reichenberg A, Gorman JM, Dieterich DT.

AIDS. 2005 Oct;19 Suppl 3:S174-8.

PMID:
16251815
18.

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.

Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, Key NS, White GC, Lindblad L, Rickles FR, Abshire TC.

Hepatology. 2002 Oct;36(4 Pt 1):967-72.

PMID:
12297845
19.

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.

Bain VG, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ, Patel K, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM.

Clin Gastroenterol Hepatol. 2008 Jun;6(6):701-6. doi: 10.1016/j.cgh.2008.02.056. Epub 2008 May 7.

PMID:
18467185
20.

HIV and hepatitis C co-infection.

Dwyer JT, Paul SM.

N J Med. 2003 Sep;100(9 Suppl):50-4; quiz 77-8. Review.

PMID:
14556604
Items per page

Supplemental Content

Write to the Help Desk